Breakthrough Genomics, a leader in genomic diagnostics, has partnered with the PRECEDE Consortium to enhance the clinical adoption of its BT-Reveal™ Early Pancreatic Cancer Test. This blood-based test, powered by Singlera's MethylTitan technology, identifies pancreatic cancer at its earliest stages using circulating cell-free DNA and patented DNA methylation technology. It has received the FDA’s Breakthrough Device Designation and is available to high-risk patients through Breakthrough Genomics’ CAP and CLIA-certified lab in Southern California.
Early detection is crucial, as pancreatic cancer is often diagnosed late, leading to limited treatment options and a persistently high mortality rate. BT-Reveal’s innovation aims to transform this prognosis by enabling detection before symptoms emerge, potentially saving countless lives.
The partnership with PRECEDE provides access to a global network of pancreatic cancer researchers and clinicians. PRECEDE, led by renowned surgeon-scientist Dr. Diane Simeone, is conducting the largest longitudinal study on pancreatic cancer, with over 7,000 patients enrolled across 54 institutions.
Developed from UC San Diego's bioengineering research and further refined by Singlera Genomics, BT-Reveal has demonstrated its potential to reduce unnecessary procedures and improve diagnostic accuracy. At PRECEDE’s Annual Meeting, Breakthrough Genomics highlighted its mission to increase the 5-year survival rate for pancreatic cancer by 400% within the next decade.
As Pancreatic Cancer Awareness Month highlights ongoing efforts to combat this disease, Breakthrough Genomics remains committed to advancing early detection and improving outcomes for patients worldwide.